Research Article
Duration of Acute Kidney Injury and In-Hospital Mortality in Elder Patients with Severe COVID-19: A Retrospective Cohort Study
Table 2
Complications, treatments and outcomes of patients between transient AKI, persistent AKI, and non-AKI with coronavirus disease 2019.
| | Characteristic | Non-AKI group (59, 55.1) | Transient AKI (11, 22.9) | Persistent AKI (37, 77.1) | valuea |
| | Complications | | | | | | Acute respiratory distress syndrome | 19 (32.2) | 5 (45.5) | 24 (64.9) | 0.007 | | Hypoproteinemia | 22 (37.3) | 4 (36.4) | 15 (40.5) | 0.941 | | Septic shock | 9 (15.3) | 4 (36.4) | 25 (67.6) | <0.001 | | Disseminated intravascular coagulation | 3 (5.1) | 1 (9.1) | 5 (13.5) | 0.358 | | Treatment | | | | | | Antibiotic therapy | 55 (93.2) | 11 (100.0) | 35 (94.6) | 0.492 | | Glucocorticoids | 51 (86.4) | 10 (90.9) | 30 (81.1) | 0.651 | | Intravenous immunoglobulin therapy | 32 (54.2) | 4 (36.4) | 25 (67.6) | 0.149 | | Need for vasopressors | 9 (15.3) | 7 (63.6) | 22 (59.5) | <0.001 | | Oxygen therapy | 57 (96.6) | 9 (81.8) | 33 (89.2) | 0.163 | | Non-invasive mechanical ventilation | 26 (44.1) | 10 (90.9) | 31 (83.8) | <0.001 | | Invasive mechanical ventilation | 16 (27.1) | 9 (81.8) | 30 (81.1) | <0.001 | | Continuous renal replacement therapy | 3 (5.1) | 2 (18.2) | 15 (40.5) | <0.001 | | Extracorporeal membrane oxygenation | 1 (1.7) | 1 (9.1) | 2 (5.4) | 0.419 | | Time from symptom onset to hospital admission (days) | 16 (12–26) | 14 (7–22) | 13 (8–20) | 0.035 | | Time from symptom onset to ICU admission (days) | 21 (14–36) | 24 (17–33) | 17 (14–26) | 0.136 | | Length of hospital stay (days) | 26 (16–40) | 32 (14–49) | 13 (7–23) | <0.001 | | Length of ICU stay (days) | 9 (5–15) | 6 (3–36) | 7 (4–13) | 0.618 | | In-hospital mortality | 11 (18.6) | 8 (72.7) | 32 (86.5) | <0.001 |
|
|
Abbreviations: AKI: acute kidney injury; ICU: intensive care unit. a values represent the comparability across the three groups. |
